Dear Reader,
Good morning! I hope you’re having a good Friday the 13th. Oooh.
I have young kids so these things are still fun for me.
Today I want to talk about biotech (some would call that a spooky subject, but hear me out).
I was talking to a friend of mine yesterday and he said, “you guys still have a biotech service? How is that possible?”
And it reminded me of when I first started Biotech Insider.
===
NVIDIA buys 7 million shares of AI-biotech.
There’s an AI biotech selling for under $10 a share that seems poised to soar in 2024…
ARK Investment recently bought 6.8 million shares…
Bayer just signed a deal worth as much as $1.5 billion to have them develop new drugs…
And NVIDIA has just partnered with them.
Get the name of the stock here.
===
Remember, I got very sick.
In my journey to getting better, I started thinking about biotech stocks.
Before I got sick, I felt like a young man.
And then when you get sick that kind of turns you old pretty quick, in a way.
I had never thought about my health before…
I’d been blessed with good health throughout my life, so getting sick like that was shocking.
But the benefit of it is, it gave me more humility…
It taught me to be grateful for every day that God gives me on earth…
It gave me a lot of gifts.
And one of the gifts was that it sparked my love for biotech stocks.
I had never really thought about them before.
When I first started thinking about biotech stocks, I talked to friends in the industry and realized there weren’t any biotech newsletters out there.
“Why is that?” I wondered.
Everyone told me, “that’s because they never work…”
If you have doctors and scientists picking the stocks, well, doctors and scientists are often terrible stock pickers…
And professional investors don’t know enough about the science.
But I was not going to be dissuaded by that at all…
As a matter of fact, it sounded like a challenge for me.
I looked at it kind of like when Carl Sagan did that series, Cosmos, on space…
I remember watching that when I was a kid and just being amazed at how he was sharing his love of space.
In the very first episode, he says, “Come with me on a journey … in our imaginary spaceship.”
And that’s how I looked at Biotech Insider…
I was going to bring people on a journey through biotechnology and healthcare and medicine.
Well, this year we celebrated our anniversary – we’re on our 7th year now…
We’ve done pretty well, and you guys get all the credit…
Our average return on all trades from April 1, 2018 to now has been over 50%.
It’s not always easy – biotech stocks can be fickle. You can be up over 400% in one and the next one you recommend is down 60%. So it’s definitely not for the faint of heart! Or stomach.
But I think the reason we’ve done so well is my enthusiasm and love for the discovery process of seeing how these things work… trying to understand this revolution in medicine that’s happening. It truly is a revolution.
And it really traces back to the ‘90s when Wall Street pressured big pharma to shrink their Research & Development departments.
So a lot of the excessive R&D got pushed out as pharma companies started trying to earn higher returns on investment.
Then all these little R&D companies started sprouting up in Boston and California, etc.
These are like the R&D shops that would have been in a big pharma giant but now that they’re independent companies, some of them are working on fabulous drugs, and we’ve been able to take advantage of that.
I was just going through the customer file for Biotech Insider, and I’ll tell you something – we have hundreds of people have been customers since our very first year and have ridden this journey with us over the last 6-7 years.
And I have to thank you so much and tell you how grateful I am that you have fought with us through the good times and the bad times…
I know they haven’t all been good times. We’ve seen biotech winters, too.
So, thank you.
Have a wonderful weekend, and God bless you.
“The Buck Stops Here”
P.S. I recorded this video about my favorite biotech play.
It’s an AI biotech selling for under $10 a share that looks poised to take off…
NVIDIA just partnered with them, and bought 7 million shares…
ARK Investment recently bought almost as many…
Bayer just signed a deal worth as much as $1.5 billion to have them develop new drugs…
Here’s the stock report.